Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Eli Lilly announced Phase 3 ATTAIN-1 trial results for orforglipron, an oral GLP-1 receptor agonist, showing significant weight loss in adults with obesity or overweight without diabetes
The effects of natural products have been also demonstrated
Results Patients were 59.4 years old (12.9 years) and 5.7 years (4.6 years) past their metastatic diagnosis of either HER2+ (n=60), HR+/HER2- (n=155) or triple negative (n=24) breast cancer
Accessed February 06, 2025
US$ 20.93
US$ 21.89
US$ 24.59
US$ 24.75
